Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

5-Hydroxytryptamine Receptor 2C

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_55

Synonyms

Historical Background

The 5-hydroxytryptamine-type 2C receptor (5-HT2C, previously 5-HT1C) is one of the 14 G protein-coupled receptor subtypes activated by serotonin. 5-HT2C receptors are involved in a large variety of physiological functions such as nociception, motor behavior, endocrine secretion, thermoregulation, modulation of appetite, and the control of exchanges between the central nervous system and the cerebrospinal fluid. They have also been implicated in numerous pathologies such as schizophrenia, anxiety, depression, Parkinson’s disease, drug addiction, and obesity (Berg et al. 2008; Chagraoui et al. 2016). In line with their implication in various pathological situations, 5-HT2C receptors are considered as a major pharmacological target for the development of new treatments (see  “Ligand-Dependent Nuclear Receptor Corepressor (LCoR)”) (Di Giovanni and De Deurwaerdere 2016).

With regard to signaling, 5-HT2C receptors are positively coupled to phospholipase Cß protein via Gαq in several brain regions (Berg et al. 2008). Native 5-HT2C receptors also activate phospholipase D through a mechanism involving Gα13 and Gβγ subunits in choroid plexus. Transactivation of the small GTPase RhoA seems to be required for 5-HT2C receptor-mediated phospholipase D activation. Activation of phospholipase A2 and ERK1,2 by 5-HT2C receptors has also been reported in heterologous cells and/or native tissues (Berg et al. 2008; Cassier et al. 2017; Labasque et al. 2008).

Protein Function

5-HT2C receptors expressed along ascending dopaminergic pathways play a prominent role in the control of mesocorticolimbic and nigrostriatal dopaminergic systems. Constitutive and/or agonist-induced 5-HT2C receptor activation inhibits dopamine release (Berg et al. 2008; Bubar and Cunningham 2008). Atypical antipsychotics and antidepressants, in particular those exhibiting inverse agonist activity at 5-HT2C receptors, relieve this inhibition, leading to activation of the mesocorticolimbic dopaminergic system (Berg et al. 2008). Systemic administration of RO600175 (agonist) and SB242084 (antagonist) inhibits and potentiates cocaine-induced behaviors, respectively. Microdialysis of RO600175 or SB242084 in the ventral tegmental area (VTA) or nucleus accumbens also revealed that dopamine efflux induced by systemic cocaine injection is controlled by 5HT2C receptors expressed in the VTA and the Nac (Berg et al. 2008; Bubar and Cunningham 2008).

5-HT2C receptor activation, likewise, exerts a tonic inhibitory influence on the activity of locus coeruleus-derived noradrenergic pathways innervating cortico-limbic structures.

5-HT2C receptors are expressed in pro-opiomelanocortin (POMC)/cocaine amphetamine-regulated transcript neurons of the arcuate nucleus of hypothalamus (Heisler et al. 2003). A series of elegant studies has shown that 5-HT2C receptor activation by administration of fenfluramine, a 5-HT reuptake inhibitor/5-HT releasing compound or by selective agonists like BVT.X, regulates melanocortin signaling and inhibits food intake (Heisler et al. 2003; Miller 2005). Studies showed that mice lacking 5-HT2C receptors displayed hepatic insulin resistance. Moreover, 5-HT2C receptor-deficient mice are resistant to the antidiabetic effects of the 5-HT2C agonist mCPP. Specific re-expression of 5-HT2C receptors in POMC neurons restored the wild-type phenotype (Xu et al. 2010), underlying the potential of 5-HT2C agonists for the treatment of obesity.

More recently, an elegant study has demonstrated that 5-HT2C receptors promote anxiety and fear. Indeed, 5-HT2C receptors modulate the activity of putatively GABAergic neurons expressing the neuropeptide corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis inducing the inhibition of anxiolytic outputs to the ventral tegmental area and lateral hypothalamus (Marcinkiewcz et al. 2016) (Fig. 1).
5-Hydroxytryptamine Receptor 2C, Fig. 1

Model of a serotonin-sensitive inhibitory microcircuit modulating anxiety and aversive learning. Serotonin inputs from the dorsal raphe (DR) to the bed nucleus of the stria terminalis (BNST) activate 5-HT2C receptors expressed in corticotropin-releasing factor (CRF) interneurons. Then, activated CRF interneurons inhibit anxiolytic outputs to the ventral tegmental area (VTA) and lateral hypothalamus (LH) promoting fear and anxiety

5-HT2C receptors are also expressed in basolateral nucleus of amygdala where they contribute to neuropathic pain mechanism. A recent study performed in a rat model of neuropathic pain has shown that local 5-HT2C receptors’ knockdown in the amygdala input region (basolateral nucleus) inhibits neuronal activity in the amygdala output region (central nucleus) by normalizing the imbalance between excitatory drive and synaptic inhibition. This imbalance between excitatory and inhibitory drive of amygdala output neurons might result from an increase 5-HT2C receptor expression in non-GABAergic cells in the basolateral nucleus (Ji et al. 2017).

Indeed, 5HT2C receptor-deficient mice are obese due to an abnormal control of feeding behavior (Berg et al. 2008). Developmental studies of food intake have revealed a chronic hyperphagia in young mutants (from the first 2 months of life through the first year of age) without changes in their body weights, adiposity levels, and in total energy expenditure, compared to wild-type animals (Nonogaki et al. 2003; Nonogaki et al. 1998). In contrast, by 9/10 months of age, mutants exhibit elevations of body weight and adiposity, accompanied by an increase in leptin and insulin levels and a reduction in the total energy expense in older mutant animals (Nonogaki et al. 1998, 2003).

Mice lacking 5HT2C receptors exhibit lower thresholds for the expression of generalized seizures (Applegate and Tecott 1998), an effect modulated by other genetic factors and aging (Brennan et al. 1997).

Mutant mice also exhibit an anxiolytic phenotype (Heisler et al. 2007) and an increased responsiveness to novelty. They are also more sensitive to the effects of acute cocaine treatment on both locomotor activity and on nucleus accumbens dopamine levels (Bubar and Cunningham 2008). Mutant mice display an approximately 50% reduction in DOI-induced head-twitch response compare to their wild-type littermates, suggesting the involvement of 5-HT2C receptors in the psychoactive response to hallucinogenic drugs (Canal et al. 2010).

Regulation of Concentration and Activity

Exposure of 5-HT2C receptors to agonists leads to receptor desensitization (i.e., a decrease in receptor responsiveness) and downregulation (i.e., a reduction in the total number of specific receptor binding sites without a change in apparent affinity for 5-HT) in vivo and in vitro (Bockaert et al. 2006). Several studies indicated that chronic treatment with antagonists and monoamine oxidase inhibitors induces an atypical downregulation of 5-HT2C receptor in the choroid plexus as well as in several heterologous models (Berg et al. 2008). Chronic administration of SSRIs increases 5HT2C receptors density in the choroid plexus (Berg et al. 2008; Bockaert et al. 2006). Paradoxically, the density and functional status of 5-HT2C receptors is also elevated in experimental models of depression as well as in depressed patients (Berg et al. 2008).

Desensitization is initiated by receptor phosphorylation by G protein receptor kinase (GRK)2 (Berg et al. 2008). Receptor phosphorylation is followed by the recruitment of β-arrestins, which uncouple receptor from G protein and promote its internalization into endosomes. This phenomenon not only contributes to receptor desensitization but also allows receptor dephosphorylation and recycling to the plasma membrane in a fully resensitized state.

In addition to agonist-dependent activation, 5-HT2C receptors undergo constitutive activity. Constitutive activity toward phospholipase C effector pathway is accompanied by constitutive receptor desensitization and internalization (Berg et al. 2008). Constitutive activity at 5-HT2C receptors expressed on VTA GABAergic interneurons is responsible for tonic inhibition of mesocorticolimbic dopaminergic neurons (De Deurwaerdere et al. 2004).

RNA transcripts encoding the 5-HT2C receptor undergo adenosine to inosine editing at five sites located in the second intracellular loop in the receptor sequence, theoretically generating up to 32 different mRNAs that encode 24 receptor isoforms, ranging from the non-edited form (INI) to the fully edited one (VGV) (Fig. 2). The 5-HT2C receptor is to date the only known GPCR for which pre-mRNA editing generates multiple functional variants. RNA editing has multiple consequences on receptor function:
  1. 1.

    Edited forms exhibit decreased constitutive activity, decreased agonist affinity, and decreased potency to activate phospholipase C (Sanders-Bush et al. 2003; Werry et al. 2008).

     
  2. 2.

    The non-edited 5-HT2C receptor is capable of coupling to Gα13 protein, whereas the fully editing one fails to activate Gα13 (Sanders-Bush et al. 2003; Werry et al. 2008).

     
  3. 3.

    The non-edited form exhibits a constitutive activity at β-arrestin- and calmodulin-dependent ERK signaling (Labasque et al. 2010).

     
  4. 4.

    Editing alters 5-HT2C receptor trafficking in and out of the plasma membrane, a process reflecting their ability to associate with β-arrestins (Marion et al. 2004).

     
5-Hydroxytryptamine Receptor 2C, Fig. 2

RNA editing of 5-HT2C receptor transcripts. (a) The position of the editing sites (A, B, C, D, and the minor site E) within the exon V of human 5-HT2C receptor mRNA and the predicted amino acid sequences are shown for the non-edited INI isoform and for the fully edited VGV isoform. (b) 5-HT2C receptor editing efficiency at each editing site for human brain (blue bars) and rat brain (brown bars)

Editing is modulated by 5-HT itself. Depletion of 5-HT increases the expression of receptor forms exhibiting the highest agonist affinity, whereas opposite changes of editing profile are detected following 5-HT2C receptor activation (Sanders-Bush et al. 2003; Werry et al. 2008). A study performed on mutant mice solely expressing the fully edited form of the receptor has suggested that editing may regulate the density of 5-HT2C receptor binding sites in the brain (Olaghere da Silva et al. 2010).

Altered patterns of 5-HT2C receptor editing are observed in postmortem brains from suicide victims with a history of major depression. Chronic treatments with antidepressants generate opposite changes of editing profiles (Sanders-Bush et al. 2003; Werry et al. 2008). Moreover, early life stress alters adult 5-HT2C receptor mRNA editing and expression of Gαq protein. Kishore and Stamm reported that Prader-Willi syndrome patients (characterized by neonatal muscular hypotonia, early childhood obesity, hypogonadism, and mental retardation) do not express the small nucleolar RNA Snord115 (previously called HBII-52), a regulator of 5-HT2C receptor mRNA splicing. These patients exhibit abnormally low levels of non-edited 5-HT2C-INI receptor. Moreover, mutant mice solely expressing the fully edited form of the receptor display phenotypic characteristics of Prader-Willy syndrome, suggesting a role of serotonergic systems in Prader-Willi syndrome (Garfield et al. 2016; Morabito et al. 2010).

Polymorphism is another mechanism contributing to receptor diversity. Three single nucleotide polymorphisms (SNPs) have been found in the promoter region of the receptor that may regulate the expression level of the 5-HT2C receptor and confer resistance to obesity and type II diabetes (Buckland et al. 2005; Deckert et al. 2000; Meyer et al. 2002; Nocjar et al. 2015; Risselada et al. 2012; Yuan et al. 2000). One non-synonymous SNP (C23S), identified in the coding region of the receptor (Lappalainen et al. 1995; Nocjar et al. 2015), does not seem to have functional consequences (Fentress et al. 2005; Nocjar et al. 2015). Another SNP was also found in the 3′ untranslated region (Nocjar et al. 2015; Song et al. 1999).

Several studies have also demonstrated a critical role of 5HT2C receptors in the onset time of therapeutic response to antidepressants (Berg et al. 2008). Long-term treatment with selective 5-HT reuptake inhibitors (SSRIs) and other antidepressant classes progressively downregulates 5HT2C receptor in rats and human, a process paralleling their gradual onset of actions.

The 5-HT2C receptor is certainly one of the G protein-coupled receptors for which the largest number of G protein-coupled receptor-interacting proteins has been identified. Those proteins clearly control G protein-coupled receptors subcellular localization, as well as nature, kinetics, strength, and fine-tuning of G protein-coupled receptors signaling. 5-HT2C receptor interacts with a number of PDZ domain-containing proteins including multiple PDZ domain protein (MUPP1), postsynaptic density protein 95 (PSD95), MAGUK p55 subfamily member 3 (MPP3), Veli3, synapse-associated protein 97 (SAP97), synapse-associated protein 102 (SAP102), and MAGI2 (for membrane-associated guanylate kinase, WW and PDZ domain containing 2) via its C-terminal PDZ binding motif (−SSV) (Becamel et al. 2002, 2004). MUPP1 was the first 5-HT2C receptor-interacting protein identified using the yeast two-hybrid system (Ullmer et al. 1998). The interaction between 5-HT2C receptors and MUPP1 is dynamically regulated by agonist-dependent receptor phosphorylation of serine residues located in the PDZ binding motif (Parker et al. 2003). Receptor/MUPP1 interaction induces both conformational changes in the MUPP1 protein (Parker et al. 2003) and receptor clustering at the cell surface (Becamel et al. 2001). The 5-HT2 like Caenorhabditis elegans receptor SER-1 similarly interacts with a multi-PDZ domain containing protein similar to MUPP1 (designated as MPZ-1) in vulval muscle cell. This interaction facilitates SER-1 signaling (Xiao et al. 2006). PDZ partners of 5-HT2C receptor exhibit both presynaptic and postsynaptic localizations consistent with the differential distribution of the receptors at the synaptic junction. Several studies using receptors mutated on the PDZ ligand indicate that 5-HT2C receptor/PDZ protein interactions play a critical role in modulating their signal transduction properties and their desensitization (Gavarini et al. 2006). Interestingly, the effects depend on the nature of the PDZ protein associated with the receptor. For instance, association of the receptor with PSD-95 increases receptor desensitization and internalization, whereas its association with MAGUK p55 subfamily member 3 (MPP3) prevents receptor internalization (Fig. 3a, b). These opposite actions highlight the importance of identifying which PDZ protein is associated with the receptor at a given time within a given neuron in native brain tissue.
5-Hydroxytryptamine Receptor 2C, Fig. 3

Interaction of 5-HT2C receptors with accessory proteins: modulation of receptor phosphorylation state and plasma membrane localization. (a and b) Opposite effect of PDZ proteins on 5HT2C receptors desensitization and trafficking. 5-HT2C receptors interact with MPP3 and PSD95 PDZ-containing proteins via their PDZ ligand (SSV) located at their carboxy-terminal extremity. PSD95 increases desensitization of the Ca2+ response as well as constitutive and agonist-induced receptor internalization, whereas MPP3 stabilized the receptor at the plasma membrane and prevented desensitization of the receptor Ca2+ response. (c) Model of assembly of liganded 5-HT2C receptor with calmodulin and β-arrestin 2. In the presence of 5-HT, β-arrestin 2 binds to 5-HT2C receptor, probably via a recognition motif located in the i2 loop and common to the rhodopsin family GPCRs. β-arrestin 2 is also connected to receptor C-terminus by a Ca2+-CaM dimer that binds to the receptor upon agonist stimulation. This CaM-dependent scaffold might function to stabilize 5-HT2C receptor/β-arrestin complex. (d) PTEN associated with the third intracellular loop of the 5-HT2C receptor induces receptor dephosphorylation and thereby reinforces effects of drugs of abuse

PSD95 is essential for maintaining normal 5-HT2C receptor expression level and downstream signaling in vivo. PSD95null mice exhibit a significant reduction in 5-HT2C expression level particularly in the striatal and hippocampal regions and display a decrease in c-fos induction upon 5-HT2C receptor activation (Abbas et al. 2009). As previously reported for the association of 5-HT2C receptors with MUPP1, the interactions between the receptor and both PSD-95 and MPP3 are negatively regulated by the phosphorylation of 5-HT2C receptors on the PDZ ligand (Ser457, Ser458) (Gavarini et al. 2006).

5-HT2C receptors also interact with non-PDZ proteins. These include calmodulin, which binds to the receptor C-terminus (Becamel et al. 2002; Labasque et al. 2008). Additional calmodulin binding motifs have been identified in intracellular loops of the 5-HT2C receptor (Labasque et al. 2008). A combination of genetic and molecular approaches indicated that activation of Erk1,2 by 5-HT2C receptor, which is entirely independent of receptor’ cognate G proteins, requires a physical association of CaM with the juxta-membrane region of the receptor C-terminus. CaM requirement was established in both heterologous system and authentic cellular contexts such as cortical neurons and choroid plexus epithelial cells. Differing from the classic mechanism of Erk1,2 activation by numerous GPCRs, phosphorylation of Erk1,2 induced by 5-HT2C receptor activation was entirely dependent on β-arrestins, which thereby acts in concert with CaM to activate Erk (Fig. 3c). More recently, it was demonstrated in HEK cells that β-arrestin2, Raf, and MEK are recruited to agonist-stimulated 5-HT2C receptor, resulting in MEK activation. Then, active MEK phosphorylates β-arrestin2 at Thr383 allowing the recruitment of Erk to the receptor/β-arrestin complex and its activation (Cassier et al. 2017).

It was also shown that 5HT2C receptors, Src, and GluN2A subunits are in a same multiprotein complex in synaptosomes from rat spinal cord and that GluN2A subunits and 5HT2C receptors co-localize on the processes of spinal neurons. Moreover, both receptors are functionally coupled as 5HT2C receptors positively modulate NMDA-mediated motoneuronal depolarization, through non-G protein-mediated mechanisms, by increasing the phosphorylation of the tyrosine kinase Src on its residue 416 (Bigford et al. 2012; Nocjar et al. 2015).

5-HT2C receptors interact with β-arrestins (mainly β-arrestin2) via their second intracellular loop (Berg et al. 2008). RNA editing of 5-HT2C receptors directly influences receptor interaction with β-arrestin2 (Marion et al. 2004). The unedited 5-HT2C-INI receptor is capable of interacting with β-arrestin2 in the absence of agonist, leading to constitutive receptor internalization and its accumulation within endocytic vesicles. Application of inverse agonists induces a marked redistribution of 5-HT2C-INI receptors to the plasma membrane of HEK-293 cells (Chanrion et al. 2008; Marion et al. 2004). Fully edited 5-HT2C-VGV receptors, which display the lowest level of constitutive activity, do not associate with β-arrestin2 in the absence of agonist and are mainly detected at the cell surface. Nevertheless, upon agonist treatment, the fully edited receptor associates with β-arrestin2 and undergoes rapid internalization.

5-HT2C receptors physically interact via their third intracellular loop with the tumor suppressor PTEN, an enzyme exhibiting both lipid and protein phosphatase activities (Ji et al. 2006). PTEN (for phosphatase and tensin homolog) association with 5-HT2C receptors prevents agonist-induced receptor phosphorylation at serine residues located in the receptor PDZ motif (Fig. 3d). Interaction between PTEN and 5-HT2C receptors occurs in dopaminergic neurons of the ventral tegmental area innervating the NAC, which are tonically inhibited by activated 5-HT2C receptors. This interaction plays an important role in mediating the reinforcing role of drugs (Ji et al. 2006).

Major Sites of Expression and Subcellular Localization

5-HT2C receptors are exclusively expressed in the CNS. 5-HT2C receptors were first identified by radioligand binding using [3H]-5-HT and [3H]-mesulergine in pig choroid plexus. Further studies using autoradiography with [3H]-mesulergine confirmed highest receptor density in choroid plexus in all mammalian species. 5-HT2C receptors expressed in choroid plexus control the secretion of the cerebrospinal fluid (Sanders-Bush et al. 2003). High receptor densities were detected in the substantia nigra, globus pallidus and ventromedial thalamus. A large amount of 5-HT2C receptors was also detected in the suprachiasmatic nucleus where they may be involved in the circadian rhythm. Several studies have shown that 5HT2C receptors are expressed on GABAergic and dopaminergic neurons within the rat ventral tegmental area and on GABAergic neurons within the prelimbic prefrontal cortex, a subregion of the medial prefrontal cortex (Berg et al. 2008; Bubar and Cunningham 2008; Bubar et al. 2011). Immunohistochemistry experiments with confocal microscopy have suggested that 5-HT2C and 5-HT2A receptors may be commonly co-expressed on GABAergic cells within the deep layers of the prelimbic mPFC and perhaps co-localized on a small population of local pyramidal projection cells (Nocjar et al. 2015). 5HT2C receptors are also expressed on glutamatergic neurons of the subthalamic nucleus and the pyramidal cells of the amygdala (Bonn et al. 2013).

[3H]-mesulergine binding in monkey and human brains followed by receptor autoradiography has revealed both pre- and postsynaptic localizations of 5-HT2C receptor (Berg et al. 2008) which were further confirmed by electron-microscopy studies (Becamel et al. 2002). 5-HT2C receptors exist as constitutive homodimers at the plasma membrane of living cells (Berg et al. 2008; Mancia et al. 2008). Two distinct dimerization interfaces have been characterized: the first one, located at TMI, is insensitive to receptor activation state, whereas the second one, located between TMs IV and V, depends on the nature of the ligand bound to receptors ((Herrick-Davis et al. 2007, 2015). It was recently shown that 5-HT2C receptors are also able to form functional heterodimers with 5-HT2A or 5-HT2B receptors when co-express in transfected cells or in neurons. This heterodimerization with 5-HT2C receptors does not alter 5-HT2C Gαq-dependent inositol-phosphate signaling; however 5-HT2A- or 5-HT2B-receptor-mediated signaling is totally blunted (Moutkine et al. 2017).

As previously mentioned, cell surface expression of 5-HT2C receptor isoforms decreases in parallel with the degree of their constitutive activity (Marion et al. 2004). Inverse agonist treatments induce redistribution to the cell surface of constitutively active 5-HT2C receptors (Marion et al. 2004).

Ligands Interacting with the 5-HT2C Receptor

In line with its broad localization and physiological functions, the 5-HT2C receptor is considered as a therapeutic target for treating obesity, obsessive-compulsive disorder, drug abuse, sleep disorders, and anxiodepressive states (Jensen et al. 2010). During the last decade, the characterization of selective 5HT2C receptor ligands has been complicated by its close structural homology with the two other 5-HT2 receptor subtypes, namely, the 5-HT2A and 5-HT2B receptors. Accordingly, many compounds bind with high affinity to all three receptor subtypes.

Anorexic Properties of Agonists

5-HT2C receptors are activated by a variety of synthetic agonists such as RO60–0175, WAY163909, WAY 161503, YM348, VER2692, and BTV.X, which reduce food intake in rodents and enhance satiety (Jensen et al. 2010). More recently, lorcaserin (ADP356) was characterized as a novel selective, high-affinity 5HT2C receptor agonist, which reduces food intake in rats (Thomsen et al. 2008).

Antidepressant Effects of 5-HT2C Ligands

Several studies have suggested that some of the therapeutic effects of serotonin reuptake inhibitors (SSRIs) are mediated in part by the 5HT2C receptor. Chronic treatment with SSRI is associated with the downregulation of 5HT2C receptors. This may lead to a disinhibition of the mesolimbic dopamine system that might contribute to their antidepressant action (Berg et al. 2008; Bubar and Cunningham 2008; Jensen et al. 2010). Numerous clinically effective antidepressants act as antagonists at 5-HT2C receptors. These include amitriptyline and clomipramine (tricyclics), trazodone and nefazodone (both behave as weak SSRI), citalopram and fluoxetine (SSRIs) (Berg et al. 2008), and agomelatine (a mixed 5-HT2C antagonist/melatonin agonist) (de Bodinat et al. 2010). Tetracyclic antidepressants such as mianserin and mirtazapine, which behave as antagonists of α2-adrenergic receptors and 5-HT3 receptors, were recently identified as inverse agonists at 5-HT2C receptors based on their ability to suppress basal inositol-phosphate production and to increase plasma membrane localization of unedited 5-HT2C-INI receptors in HEK-293 cells as well as in cortical cultured neurons (Chanrion et al. 2008). Paradoxically, 5-HT2C receptor agonists such as WAY161503, RO 60–0175, and RO 60–0332 also exhibited antidepressant-like activity in selected models of depression, an effect that might reflect their ability to promote neurogenesis (Millan 2005).

Anxiolytic Effects of Antagonists

Several 5-HT2C receptor antagonists (e.g., SB206553) exert a robust anxiolytic activity. These compounds also behave as inverse agonists at 5-HT2C receptors (Chanrion et al. 2008). Moreover, it was recently shown that mianserin is able to suppress the evoked anxiety-like behavior in crayfish (Fossat et al. 2015). Corroborating the anxiolytic action of antagonists, agonists like RO60–0175, WAY163909, and mCPP (m-chlorophenylpiperazine) display anxiogenic properties in the social interaction test (Millan 2005).

Antipsychotic Properties of Antagonists

Numerous antipsychotics act as antagonists (or inverse agonists) at 5-HT2C receptors (Berg et al. 2008; Jensen et al. 2010; Sullivan et al. 2015). Moreover, the 5HT2C inverse agonist SB 206553 potentiates the effect of haloperidol on dopamine release (Berg et al. 2008; Bubar and Cunningham 2008). It has been reported that selective 5-HT2C antagonists and agonists reduce DOI-induced head twitches. The effect of the agonists is likely due to the competition with DOI (Canal et al. 2013).

Efficacy of 5-HT2C Ligands in the Treatment of Drug Addiction

It appears that the 5-HT2C agonists or antagonists alter the behaviors induced by drugs of abuse (Canal et al. 2013; Higgins and Fletcher 2015; Howell and Cunningham 2015). Indeed, the enhancement of locomotor activity induced by cocaine is reduced by intra-VTA injection of 5-HT2C agonists and unaffected by 5-HT2C antagonists (Canal et al. 2013; McMahon et al. 2001); the expression of the behavioral sensitization associated with chronic cocaine administration is reduced by the intra-NAc application of a selective 5-HT2C antagonist (Canal et al. 2013; Zayara et al. 2011). It was also shown that SB 206553 attenuated methamphetamine seeking in rats (Canal et al. 2013; Graves and Napier 2012).

Other Properties of 5HT2C Ligands

SB242084 behaves as a neutral antagonist at 5HT2C receptor signaling via phospholipase C, whereas it acts as partial inverse agonist at phospholipase A2, suggesting that it might be a protean ligand (Chanrion et al. 2008).

PNU-69176E, a positive allosteric modulator, highly selective for 5-HT2C receptors has been characterized in different mammalian expression systems. PNU-69176E enhances [3H]-5-HT binding to the human 5-HT2C receptor by selectively increasing 5-HT affinity for its low-affinity sites without affecting antagonist binding (Berg et al. 2008).

The selective 5-HT2C R agonist lorcaserin, used for the treatment of obesity, inhibits oxycodone intake and decreases cue reactivity associated with relapse, highlighting the therapeutic potential for lorcaserin in the treatment of opioid use disorder (Canal et al. 2013; Neelakantan et al. 2017). Another 5-HT2C receptor agonist, the CP809.101, improves cognitive flexibility and reversal learning abilities (Canal et al. 2013; Del’Guidice et al. 2014).

Summary

5-HT2C receptors still raise particular attention in view of their implication in many physiological functions and behaviors and in a large spectrum of psychiatric disorders such as anxiodepressivestates, schizophrenia, obsessive-compulsive behaviors, and obesity. Accordingly, 5-HT2C receptors are considered as a major therapeutic target for the development of improved treatments of these diseases. Moreover, 5-HT2C is unique within G protein-coupled receptor superfamily to exhibit mRNA editing. Editing generates numerous 5-HT2C isoforms exhibiting different coupling properties, subcellular localization, and constitutive activity levels. Getting further insight into mechanisms controlling 5-HT2C receptor mRNA editing, signal transduction properties of receptor variants, and their interaction with accessory proteins in neurons as well as their role in synaptic transmission and synaptic plasticity is therefore essential to discover innovative approaches in psychiatric disorders related to receptor dysfunction.

References

  1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG, Roth BL. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci. 2009;29:7124–36.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Applegate CD, Tecott LH. Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis. Exp Neurol. 1998;154:522–30.PubMedCrossRefGoogle Scholar
  3. Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, Ullmer C. Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. J Biol Chem. 2001;276:12974–82.PubMedCrossRefGoogle Scholar
  4. Becamel C, Alonso G, Galeotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, Marin P. Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. EMBO J. 2002;21:2332–42.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Becamel C, Gavarini S, Chanrion B, Alonso G, Galeotti N, Dumuis A, Bockaert J, Marin P. The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins. J Biol Chem. 2004;279:20257–66.PubMedCrossRefGoogle Scholar
  6. Berg KA, Clarke WP, Cunningham KA, Spampinato U. Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications. Neuropharmacology. 2008;55:969–76.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bigford GE, Chaudhry NS, Keane RW, Holohean AM. 5-Hydroxytryptamine 5HT2C receptors form a protein complex with N-methyl-D-aspartate GluN2A subunits and activate phosphorylation of Src protein to modulate motoneuronal depolarization. J Biol Chem. 2012;287:11049–59.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006;326:553–72.PubMedCrossRefGoogle Scholar
  9. Bonn M, Schmitt A, Lesch KP, Van Bockstaele EJ, Asan E. Serotonergic innervation and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral amygdaloid nuclei. Brain Struct Funct. 2013;218:421–35.PubMedCrossRefGoogle Scholar
  10. Brennan TJ, Seeley WW, Kilgard M, Schreiner CE, Tecott LH. Sound-induced seizures in serotonin 5-HT2c receptor mutant mice. Nat Genet. 1997;16:387–90.PubMedCrossRefGoogle Scholar
  11. Bubar MJ, Cunningham KA. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res. 2008;172:319–46.PubMedCrossRefGoogle Scholar
  12. Bubar MJ, Stutz SJ, Cunningham KA. 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. PLoS One. 2011;6:e20508.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O’Donovan MC. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry. 2005;162:613–5.PubMedCrossRefGoogle Scholar
  14. Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology. 2010;209:163–74.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Canal CE, Booth RG, Morgan D. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology. 2013;70:112–21.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Cassier E, Gallay N, Bourquard T, Claeysen S, Bockaert J, Crepieux P, Poupon A, Reiter E, Marin P, Vandermoere F. Phosphorylation of beta-arrestin2 at Thr383 by MEK underlies beta-arrestin-dependent activation of Erk1/2 by GPCRs. ELife. 2017;6:e23777.Google Scholar
  17. Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT2C receptors in psychiatric disorders: a review. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;66:120–35.CrossRefGoogle Scholar
  18. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. 2008;73:748–57.PubMedCrossRefGoogle Scholar
  19. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9:628–42.PubMedCrossRefGoogle Scholar
  20. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci. 2004;24:3235–41.PubMedCrossRefGoogle Scholar
  21. Deckert J, Meyer J, Catalano M, Bosi M, Sand P, DiBella D, Ortega G, Stober G, Franke P, Nothen MM, et al. Novel 5′-regulatory region polymorphisms of the 5-HT2C receptor gene: association study with panic disorder. Int J Neuropsychopharmacol. 2000;3:321–5.PubMedCrossRefGoogle Scholar
  22. Del’Guidice T, Lemay F, Lemasson M, Levasseur-Moreau J, Manta S, Etievant A, Escoffier G, Dore FY, Roman FS, Beaulieu JM. Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation. Neuropsychopharmacology. 2014;39:1125–34.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Di Giovanni G, De Deurwaerdere P. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders. Pharmacol Ther. 2016;157:125–62.PubMedCrossRefGoogle Scholar
  24. Fentress HM, Grinde E, Mazurkiewicz JE, Backstrom JR, Herrick-Davis K, Sanders-Bush E. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms. Pharmacogenomics J. 2005;5:244–54.PubMedCrossRefGoogle Scholar
  25. Fossat P, Bacque-Cazenave J, De Deurwaerdere P, Cattaert D, Delbecque JP. Serotonin, but not dopamine, controls the stress response and anxiety-like behavior in the crayfish Procambarus clarkii. J Exp Biol. 2015;218:2745–52.PubMedCrossRefGoogle Scholar
  26. Garfield AS, Davies JR, Burke LK, Furby HV, Wilkinson LS, Heisler LK, Isles AR. Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite. Mol Brain. 2016;9:95.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Gavarini S, Becamel C, Altier C, Lory P, Poncet J, Wijnholds J, Bockaert J, Marin P. Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability. Mol Biol Cell. 2006;17:4619–31.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Graves SM, Napier TC. SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats. BMC Neurosci. 2012;13:65.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Heisler LK, Cowley MA, Kishi T, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Zigman JM, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci. 2003;994:169–74.PubMedCrossRefGoogle Scholar
  30. Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 2007;6:491–6.PubMedCrossRefGoogle Scholar
  31. Herrick-Davis K, Grinde E, Weaver BA. Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment. Eur J Pharmacol. 2007;568:45–53.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Herrick-Davis K, Grinde E, Lindsley T, Teitler M, Mancia F, Cowan A, Mazurkiewicz JE. Native serotonin 5-HT2C receptors are expressed as homodimers on the apical surface of choroid plexus epithelial cells. Mol Pharmacol. 2015;87:660–73.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Higgins GA, Fletcher PJ. Therapeutic potential of 5-HT2C receptor agonists for addictive disorders. ACS Chem Neurosci. 2015;6:1071–88.PubMedCrossRefGoogle Scholar
  34. Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev. 2015;67:176–97.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Jensen NH, Cremers TI, Sotty F. Therapeutic potential of 5-HT2C receptor ligands. ScientificWorldJournal. 2010;10:1870–85.PubMedCrossRefGoogle Scholar
  36. Ji SP, Zhang Y, Van Cleemput J, Jiang W, Liao M, Li L, Wan Q, Backstrom JR, Zhang X. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat Med. 2006;12:324–9.PubMedCrossRefGoogle Scholar
  37. Ji G, Zhang W, Mahimainathan L, Narasimhan M, Kiritoshi T, Fan X, Wang J, Green TA, Neugebauer V. 5-HT2C receptor knockdown in the amygdala inhibits neuropathic-pain-related plasticity and behaviors. J Neurosci. 2017;37:1378–93.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Labasque M, Reiter E, Becamel C, Bockaert J, Marin P. Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol Biol Cell. 2008;19:4640–50.PubMedPubMedCentralCrossRefGoogle Scholar
  39. Labasque M, Meffre J, Carrat G, Becamel C, Bockaert J, Marin P. Constitutive activity of Serotonin2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants. Mol Pharmacol. 2010;78:818–26.PubMedCrossRefGoogle Scholar
  40. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 1995;27:274–9.PubMedCrossRefGoogle Scholar
  41. Mancia F, Assur Z, Herman AG, Siegel R, Hendrickson WA. Ligand sensitivity in dimeric associations of the serotonin 5HT2c receptor. EMBO Rep. 2008;9:363–9.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Marcinkiewcz CA, Mazzone CM, D’Agostino G, Halladay LR, Hardaway JA, DiBerto JF, Navarro M, Burnham N, Cristiano C, Dorrier CE, et al. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature. 2016;537:97–101.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Marion S, Weiner DM, Caron MG. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem. 2004;279:2945–54.PubMedCrossRefGoogle Scholar
  44. McMahon LR, Filip M, Cunningham KA. Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Neurosci. 2001;21:7781–7.PubMedGoogle Scholar
  45. Meyer J, Saam W, Mossner R, Cangir O, Ortega GR, Tatschner T, Riederer P, Wienker TF, Lesch KP. Evolutionary conserved microsatellites in the promoter region of the 5-hydroxytryptamine receptor 2C gene (HTR2C) are not associated with bipolar disorder in females. J Neural Transm. 2002;109:939–46.PubMedCrossRefGoogle Scholar
  46. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60:441–60.PubMedCrossRefGoogle Scholar
  47. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv. 2005;5:282–91.PubMedCrossRefGoogle Scholar
  48. Morabito MV, Abbas AI, Hood JL, Kesterson RA, Jacobs MM, Kump DS, Hachey DL, Roth BL, Emeson RB. Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol Dis. 2010;39:169–80.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Moutkine I, Quentin E, Guiard BP, Maroteaux L, Doly S. Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers. J Biol Chem. 2017;292:6352–68.PubMedCrossRefGoogle Scholar
  50. Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, Anastasio NC, Moeller FG, Cunningham KA. Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS chem Neurosci. 2017;6b00413.Google Scholar
  51. Nocjar C, Alex KD, Sonneborn A, Abbas AI, Roth BL, Pehek EA. Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. Neuroscience. 2015;297:22–37.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998;4:1152–6.PubMedCrossRefGoogle Scholar
  53. Nonogaki K, Abdallah L, Goulding EH, Bonasera SJ, Tecott LH. Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT(2C) receptor mutant mice. Diabetes. 2003;52:315–20.PubMedCrossRefGoogle Scholar
  54. Olaghere da Silva UB, Morabito MV, Canal CE, Airey DC, Emeson RB, Sanders-Bush E. Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Front Neurosci. 2010;4:26.PubMedPubMedCentralGoogle Scholar
  55. Parker LL, Backstrom JR, Sanders-Bush E, Shieh BH. Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1. J Biol Chem. 2003;278:21576–83.PubMedCrossRefGoogle Scholar
  56. Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, Arends J, Mulder H. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 2012;12:62–7.PubMedCrossRefGoogle Scholar
  57. Sanders-Bush E, Fentress H, Hazelwood L. Serotonin 5-ht2 receptors: molecular and genomic diversity. Mol Interv. 2003;3:319–30.PubMedCrossRefGoogle Scholar
  58. Song HR, Gu A, Schanen NC. Identification of a new polymorphism in the 3′-untranslated region of the human serotonin receptor 2C (5-HT2C) gene. Mol Genet Metab. 1999;66:224–7.PubMedCrossRefGoogle Scholar
  59. Sullivan LC, Clarke WP, Berg KA. Atypical antipsychotics and inverse agonism at 5-HT2 receptors. Curr Pharm Des. 2015;21:3732–8.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577–87.PubMedCrossRefGoogle Scholar
  61. Ullmer C, Schmuck K, Figge A, Lubbert H. Cloning and characterization of MUPP1, a novel PDZ domain protein. FEBS Lett. 1998;424:63–8.PubMedCrossRefGoogle Scholar
  62. Werry TD, Loiacono R, Sexton PM, Christopoulos A. RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol Ther. 2008;119:7–23.PubMedCrossRefGoogle Scholar
  63. Xiao H, Hapiak VM, Smith KA, Lin L, Hobson RJ, Plenefisch J, Komuniecki R. SER-1, a Caenorhabditis elegans 5-HT2-like receptor, and a multi-PDZ domain containing protein (MPZ-1) interact in vulval muscle to facilitate serotonin-stimulated egg-laying. Dev Biol. 2006;298:379–91.PubMedCrossRefGoogle Scholar
  64. Xu Y, Berglund ED, Sohn JW, Holland WL, Chuang JC, Fukuda M, Rossi J, Williams KW, Jones JE, Zigman JM, et al. 5-HT(2C)Rs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci. 2010;13:1457–9.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia. 2000;43:373–6.PubMedCrossRefGoogle Scholar
  66. Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, Szumlinski KK. Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology. 2011;213:321–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Carine Bécamel
    • 1
  • Philippe Marin
    • 1
  • Joël Bockaert
    • 1
  1. 1.Dépt. de NeurobiologieInstitut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche MédicaleMontpellier Cedex 5France